About Mitochondrial potassium channel
Mitochondrial potassium channel (CCDC51) is a protein
from Homo sapiens identified by UniProt accession
Q96ER9, 411 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | Mitochondrial potassium channel |
| UniProt accession | Q96ER9 |
| Gene | CCDC51 |
| Organism | Homo sapiens |
| Length | 411 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (69)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.24
- platelet count · score 0.23
- glomerular filtration rate · score 0.08
- MODY · score 0.07
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome · score 0.05
- hemoglobin D disease · score 0.05
- delta-beta-thalassemia · score 0.05
- dominant beta-thalassemia · score 0.05
- diabetes mellitus, permanent neonatal 4 · score 0.04
- hemoglobin E-beta-thalassemia syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96ER9-F1 | alphafold | PREDICTED | 69.14 | — |
Amino-acid sequence (411 residues)
MMGRSPGFAM QHIVGVPHVL VRRGLLGRDL FMTRTLCSPG PSQPGEKRPE EVALGLHHRL PALGRALGHS IQQRATSTAK TWWDRYEEFV GLNEVREAQG KVTEAEKVFM VARGLVREAR EDLEVHQAKL KEVRDRLDRV SREDSQYLEL ATLEHRMLQE EKRLRTAYLR AEDSEREKFS LFSAAVRESH EKERTRAERT KNWSLIGSVL GALIGVAGST YVNRVRLQEL KALLLEAQKG PVSLQEAIRE QASSYSRQQR DLHNLMVDLR GLVHAAGPGQ DSGSQAGSPP TRDRDVDVLS AALKEQLSHS RQVHSCLEGL REQLDGLEKT CSQMAGVVQL VKSAAHPGLV EPADGAMPSF LLEQGSMILA LSDTEQRLEA QVNRNTIYST LVTCVTFVAT LPVLYMLFKA S
Explore Mitochondrial potassium channel with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets